|
|
 |
 |
| |
 Printable version |
Dermatologic side effects induced by new angiogenesis inhibitors |
Bulletin du Cancer. Volume 98, Number 10, 1221-9, Octobre 2011, Synthèse
|
 Résumé
Texte intégral
|
Author(s) : Vincent Sibaud, Ignacio Garrido-Stowhas, Ewa Cottura, Christine Chevreau |
Summary : While new anticancer angiogenesis inhibitors present a well-tolerated safety profile, they are not without adverse events. The signaling pathways and/or receptors inhibited by these new drugs are often physiologically expressed in the skin and/or hair follicle and cutaneous toxicity is on the forefront. This article reviews the main dermatologic adverse events induced by these targeted anticancer therapies with a partial or exclusive antiangiogenic activity: sorafenib, sunitinib, pazopanib, vandetanib, everolimus, temsirolimus or bevacizumab. |
Keywords : cutaneous adverse events, angiogenesis inhibitors, pazopanib, vandetanib, mTOR inhibitors, sorafenib |
|
